CD274 and glioblastoma: Anti-PD1 (immune checkpoint inhibitor) therapies are more likely to be effective in tumours with PD-L1 suppressing adaptive immunity,34 although regional heterogeneity in PD-L1 expression has not been fully characterized in glioblastoma.